Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical features of vaccination-associated thrombocytopenic purpura in children

예방접종과 관련된 소아 혈소판 감소 자반병의 임상적 특성

  • Lee, Wan Soo (Department of Pediatrics, Wonkwang University School of Medicine) ;
  • Yu, Seung Taek (Department of Pediatrics, Wonkwang University School of Medicine) ;
  • Shin, Sae Ron (Department of Family Medicine, Wonkwang University School of Medicine) ;
  • Young Du (Department of Pediatrics, Wonkwang University School of Medicine)
  • 이완수 (원광대학교 의과대학 소아과학교실) ;
  • 유승택 (원광대학교 의과대학 소아과학교실) ;
  • 신새론 (원광대학교 의과대학 가정의학과학교실) ;
  • 최두영 (원광대학교 의과대학 소아과학교실)
  • Received : 2008.01.07
  • Accepted : 2008.03.18
  • Published : 2008.06.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Idiopathic thrombocytopenic purpura (ITP) is a relatively common hematological disease in children. It generally occurs after exposure to a common viral infection episode; however, it may occasionally follow immunization with measles, measles-mumps-rubella (MMR), hepatitis B (HBV), influenza, diphtheria-tetanus-pertussis (DTP), or chickenpox vaccines. In this study, the incidence, clinical characteristics, and treatment outcome of vaccination-associated ITP were investigated and compared with non-vaccination-associated ITP. Methods : The admission records of 105 pediatric ITP patients between 0-14 years of age admitted to Department of Pediatrics, Wonkwang University Hospital from January 1994 to July 2007 were retrospecitively reviewed. Patients were grouped into a vaccination-associated group and a non-vaccination-associated group according to vaccination history within the previous 1 month, and various clinical features between the two groups were statistically analyzed. Results : Thirteen patients (12%) had a preceding vaccination. Eight had received DTP vaccination, 2 had received hepatitis B, and 1 each had received influenza, MMR, and Japanese B encephalitis vaccination. However, none of the patients had a recurrent thrombocytopenia after subsequent vaccinations. In the vaccination-associated group, the age was significantly lower, anemia was more common, and the risk period with blood platelet count $<20{\times}10^9/L$ was significantly shorter than for the in non-vaccination-associated group. Also, wet purpura was less prominent and the remission within 1month was more frequently achieved in the vaccination-associated ITP group. Conclusion : Vaccination-associated ITP patients showed mild symptoms with a more benign and shorter lasting course than non-vaccination-associated ITP patients. Moreover, platelet count assessment at the time of the next immunization may not be necessary.

목 적 : 소아 특발성 혈소판 감소 자반병은 대부분 바이러스 감염 후 수주 후에 발병하나 약 7%에서는 홍역, 풍진, B형 간염, 독감, 수두, DTP등의 예방 접종과 관련되어 발생함이 보고 되었다. 본 연구는 예방접종과 관련된 혈소판 감소 자반병의 빈도와 임상적 특성을 알아보고 예방접종과 관련이 없는 혈소판 감소 자반병과의 차이점을 분석하고자 하였다. 방 법 : 1994년 1월부터 2007년 7월까지 원광대학교 병원 소아과에 혈소판 감소 자반병으로 입원한 환아 105명을 대상으로 의무기록지를 이용하여 후향적으로 조사하였다. 예방접종과 관련된 혈소판 감소 자반병은 예방 접종 후 1개월 이내 발병으로 정의하였으며 예방접종관련 군과 없는 군으로 분류하여 여러 임상적 특성에 대해비교 분석하였다. 결 과 : 혈소판 감소 자반병은 총 105례였으며 이중 13례(12.4 %)가 예방접종과 관련되었고 DTP에 의한 경우가 8례로 가장 많았으며 HBV가 2례, 인플루엔자, MMR, 일본뇌염이 각각 1례였다. 예방접종과 관련된 군에서 다음 예방접종 시 혈소판 감소 자반병이 재발한 예는 없었다. 예방 접종 군에서 관련이 없는 군에 비해 진단 시 연령이 의미 있게 낮았으며 빈혈이 더 많이 동반되었으며 합병증과 관련이 있는 혈소판 $20{\times}10^9/L$ 미만의 위험기간이 짧았다. 또한 예방 접종 군에서 구강내 출혈, 혈변, 혈뇨와 비출혈과 같은 심한 증상이 적고 1개월 내 관해가 높았으나 통계학적 차이는 없었다. 결 론 : 예방접종과 관련된 혈소판 감소 자반병이 관련이 없는 경우에 비해 증상이 경미하고 양성의 경과를 보였으며 다음 예방 접종은 주의하여 정상적인 스케줄에 따라 시행하며 예방접종 후 혈소판 검사를 반드시 시행할 필요는 없을 것으로 사료된다.

Keywords

Acknowledgement

Supported by : Wonkwang University

References

  1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008 https://doi.org/10.1056/NEJMra010501
  2. Lanzkowsky P. Idiopathic thrombocytopenic purpura. Manual of pediatric hematology and oncology. New York: Academic Press, 2000:233-8
  3. James NG. Diagnosis, clinical course, and management of idiopathic thrombocytopenic purpura. Curr Opin Hematol 1996;3:335-40 https://doi.org/10.1097/00062752-199603050-00001
  4. Imbach P, Kuhne T. Immune thrombocytopenic purpura. Vox Sang 1998;74 Suppl 2:309-14 https://doi.org/10.1111/j.1423-0410.1998.tb05436.x
  5. Sandoval C, Visintainer C, Ozkaynak MF, Tugal O, Jayabose S. Clinical features and treatment outcomes of 79 infants with immune thrombocytopenic purpura. Pediatr Blood Cancer 2004;42:109-12 https://doi.org/10.1002/pbc.10458
  6. Farrington P, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995;345:567-9 https://doi.org/10.1016/S0140-6736(95)90471-9
  7. Poullin P, Gabriel B. Thrombocytopenic purpura after recombinant hepatitis B vaccine. Lancet 1994;344:1293
  8. Jadavji T, Scheifele D, Halperin S. Thrombocytopenia after immunization of Canadian children, 1992 to 2001. Pediatr Infect Dis J 2003;22:119-22
  9. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40
  10. Nieminen U, Peltola H, Syrjala MT, Makipernaa A, Kekomaki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination: a report on 23 patients. Acta Pediatr 1993;82:267-70 https://doi.org/10.1111/j.1651-2227.1993.tb12657.x
  11. Oski FA, Naiman JL. Effect of live measles vaccine on the platelet count. N Engl J Med 1996;275:352-6
  12. Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Nelson textbook of pediatrics. 18th ed. Philadelphia : Saunders Co, 2007: 2003
  13. Wang JD, Huang FL, Chen PY, Wang TM, Chi CS, Chang TKl. Acute immune thrombocytopenic purpura in infants: associated factors, clinical features, treatment and longterm outcome. Eur J Haematol 2006;77:334-7 https://doi.org/10.1111/j.1600-0609.2006.00714.x
  14. Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol 2003;55: 107-11 https://doi.org/10.1046/j.1365-2125.2003.01790.x
  15. Zeller B, Rajantie J, Hedlund-Treutiger I, Tedgard U, Wesenberg F, Jonsson OG, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: Epidemiology and predictors of chronic disease. Acta Paediatr 2005;94: 178-84 https://doi.org/10.1080/08035250410025294
  16. Yenicesu I, Yetgin S, Ozyurek E. Vaccination-associated immune thrombocytopenic purpura in five children. Pediatr Hematol Oncol 2001;18:547-9 https://doi.org/10.1080/088800101753328538
  17. Lusher JM, Zuelzer W. Idiopathic thrombocytopenic purapura in childhood. J Pediatr 1966;68:971-9 https://doi.org/10.1016/S0022-3476(66)80218-4
  18. Simons SM, Main CA, Yaish HM, Rutzky J. Idiopathic thrombocytopenic purpura in children. J Pediatr 1975;87: 16-22 https://doi.org/10.1016/S0022-3476(75)80061-8
  19. Kim KN, Cho SH, Shin JH, Lee WG. Clinical study of idiopathic thrombocytopenic purpura in children. J Korean Pediatr Soc 1985;28:251-7
  20. Newton WA Jr., Zuelzer WW. Idiopathic thrombocytopenic purpura in childhood. N Engl J Med 1951;245:879-85 https://doi.org/10.1056/NEJM195112062452302
  21. Lammi AT, Lovric VA. Idiopathic thrombocytopenic purpura: an epidemiologic study. J Pediatr 1973;83:31-6 https://doi.org/10.1016/S0022-3476(73)80308-7
  22. Walker JH, Walker W. Idiopathic thrombocytopenic purpura in childhood. Arch Dis Child 1961;36:649-57 https://doi.org/10.1136/adc.36.190.649
  23. Rajantie J, Zeller B, Treutiger I, Rosthoj S. Vaccination associated thrombocytopenic purpura in children. Vaccine 2007;25:1838-40 https://doi.org/10.1016/j.vaccine.2006.10.054

Cited by

  1. 신생아 B형 간염 예방 접종 후 하지 부종이 발생한 환아 치험 1례 vol.28, pp.1, 2014, https://doi.org/10.7778/jpkm.2014.28.1.052